ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Sacramento, California 95817, United States
Miami, Florida 33136, United States
Baltimore, Maryland 21201, United States
Baltimore, Maryland 21231, United States
St Louis, Missouri 63110, United States
Columbus, Ohio 43210, United States
Philadelphia, Pennsylvania 19107, United States
Braunschweig, 38114, Germany
Stuttgart, 70376, Germany
Alessandria, 15100, Italy
Milan, 20122, Italy
Loerenskog, 1478, Norway
Krakow, 31-501, Poland
A Coruña, Spain
Madrid, 28046, Spain
Salamanca, Spain
Bellinzona, 6500, Switzerland
Zurich, 8091, Switzerland
Inciralt, 35340, Turkey (Türkiye)
Canterbury, CT1 3NG, United Kingdom